SMC announces that Merck & Co., Inc. (NJ) has published the results of a study using STAM^TM mouse model in Cell Reports Medicine.

Title: “Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis”

In this paper, they report the results of pharmacology study of MK-8722 (AMPK activator) and MK-4074 (ACC inhibitor) using STAM^TM mouse model.

Both AMPK and ACC are attractive targets for NASH drugs. In fact, PXL770 (AMPK activator) and GS-0976 (ACC inhibitor) are actually conducting clinical trials targeting NASH patients.

If you have any interest in the evaluation of the AMPK activator and ACC inhibitor with STAM^TM mouse model, please contact us.